



PRESS RELEASE

Advanced Accelerator Applications Announces Research and Supply Partnership with the Institut Curie in Paris

Saint-Genis-Pouilly, France (July 1, 2010) - Advanced Accelerator Applications ("AAA"), an international leader in diagnostic nuclear medicine, today announced that it has signed an agreement with the Institut Curie to build, install and operate a pharmaceutical laboratory for radiopharmaceuticals production at the Institut Curie's René Huguenin specialist cancer hospital in Saint-Cloud, Paris.

The cyclotron will guarantee the supply of high quality radiopharmaceuticals for the hospital's two PET (Positron Emission Tomography) scanners, which are increasingly used in the diagnosis and treatment of cancers, enabling clinicians to track the progress of treatments such as chemotherapy as well as the appearance of secondary tumors and metastases.

René Huguenin is AAA's fifth production center in France. It will allow AAA to supply other hospitals in western France.

The new cyclotron is expected to be fully operational in 2013. It will be used to produce F-18, which is widely used in nuclear medicine in the form of FDG (Fluoro Deoxy Glucose). Also produced will be carbon-11, a research nuclide whose use has been limited by its very short half life of around 20 minutes, requiring it to be produced on site.

C-11 is a base component of all molecules and thus of all medicines, making it ideal for tracing the progress of therapeutic molecules in the body. Work on radiotracers using F-18 will initially focus on prostate cancer and lymphoma.

FDG is a glucose analog which is consumed in significant quantities by many cancerous cells and therefore shows up clearly in PET scans. This allows clinicians to determine whether or not a lesion is cancerous and to detect tiny traces of cancerous cells. Because of the short half-life of the F-18 isotope (around 110 minutes), it has to be produced in relatively large quantities to allow for decay during delivery to the patient.

Dr Alain Pecking, Associate Director of the René Huguenin comprehensive Cancer Center, commented, "*This collaboration with AAA for the installation of a cyclotron to produce isotopes reinforces the René Huguenin Hospital's leadership in the field of nuclear medicine and will help us achieve our goal of offering patients the most up to date, innovative and targeted imaging techniques.*"

"Having a cyclotron on site will allow us to conduct PET scans using products that were not feasible previously because of their short half-life. This partnership with AAA will also enable us to evaluate the bioavailability and tumoral affinity of radio-active isotopes labelled with C-11 and to develop new radiotracers with F-18."

Stefano Buono, CEO of AAA, commented, "*This is another important milestone for AAA. The Institut Curie is one of the world's leading cancer centers and this partnership provides an*"



exciting opportunity for both organizations to develop new and innovative oncology markers. There is a growing need for better oncology treatments and AAA is committed to developing innovative diagnostics and therapeutics. The partnership with the Institut Curie will significantly strengthen our position in this market.”

About Institut Curie:

The Institut Curie is a private foundation created by Marie Curie in 1909 for the treatment, diagnosis and research of cancer. It is world leader in cutting-edge innovation in oncology care, combining France’s largest oncology research center with a state-of-the-art hospital, and is a center of excellence for the treatment of breast cancer, pediatric tumors and ocular tumors. It has pioneered numerous cancer treatments and medical innovations. Its 3,000 researchers, physicians and healthcare workers are united by the same ambition, to defeat cancer.

For more information, visit www.curie.fr

About Advanced Accelerator Applications:

Founded in 2002, Advanced Accelerator Applications is a European pharmaceutical group. It develops and commercializes innovative diagnostic and therapeutic applications and products. AAA’s main research focus is on molecular imaging and personalized medicines for the treatment of diseases where there is a clear and not met medical need, including cancer. The Company is a European leader in the production and commercialization of PET (Positron Emission Tomography) radiopharmaceuticals. PET is the most sophisticated diagnostic technique currently available and is used mainly in clinical oncology, cardiology and neurology. The Company has an interdisciplinary team of 130 employees, working in 10 production and R&D facilities in France, Italy, Switzerland, Spain and the USA. It has a particularly strong market position in France with its laboratories in Saint Genis Pouilly, also AAA’s headquarters, in Troyes and in Béthune.

In March 2010, AAA invested in Atreus Pharmaceuticals Corporation, a Canadian company. The objective of this investment is to accelerate the development of Annexin V-128, its leading radiopharmaceutical compound. Annexin is an apoptosis and necrosis marker for a number of conditions including rheumatoid arthritis. In June 2010, AAA entered the American market with the acquisition of BioSynthema, Inc. This company discovers and develops unique pharmaceuticals targeted to cell surface receptors over-expressed by various lesions, e.g. neuroendocrine cancers. BioSynthema is currently developing compounds that will bring new and effective products to the market for the diagnosis and treatment of Gastro-Entero-Pancreatic NeuroEndocrine Tumors (GEPNETs), including its lead product Lutate.

For more information, visit www.adacap.com



Contacts

Advanced Accelerator Applications SA

Véronique Mermet
20 rue Diesel
01630 Saint Genis Pouilly, France
Tel: +33 4 50 99 30 70
www.adacap.com
info@adacap.com

Institut Curie

Céline Giustranti
26 rue d'Ulm
75248 Paris Cedex 05
Tél. +33 1 56 24 55 24
www.curie.fr
service.presse@curie.fr

FD Financial Communications

AAA's Communication Agency
Stephanie Cuthbert
Email: Stephanie.Cuthbert@fd.com
T +44 (0)20 3077 0458

Jonathan Birt
Email: Jonathan.Birt@fd.com
T +44 (0)20 7269 7205